Clearmind Medicine to Collaborate with Johns Hopkins University for Alcohol Use Disorder Trial
Clearmind Medicine, Inc. (Nasdaq: CMND) has entered into a Clinical Trial Agreement with Johns Hopkins UniversitySchool of Medicine (JHU) to conduct a Phase I/IIa clinical trial of its proprietary CMND-100 as a treatment for Alcohol Use Disorder (AUD).
Clearmind is also working closely with world-renowned Yale School of Medicine’s Department of Psychiatry, which has researched the company’s potential treatment and has agreed to participate in its clinical program.
Clearmind’s Chief Executive Officer Dr. Adi Zuloff-Shani, said, “We are honored to collaborate with JHU for our first in human clinical trial. JHU is one of the global leaders in psychedelics clinical research and in researching addictions, and we are very grateful to partner with them to study our proprietary CMND-100 to treat Alcohol Use Disorder.”
CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.
Oral capsules will be administered once daily, for ten consecutive days and patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.
The study’s primary endpoint is to establish optimal dosing, safety and efficacy of single and repeated doses of CMND-100 in healthy subjects and those with Alcohol Use Disorder.
The secondary end point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and cravings, in individuals with moderate-to-severe AUD.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of fourteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.